Chester County News and Community Website
CONSHOHOCKEN, PA — The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Madrigal Pharmaceuticals’ (NASDAQ: …
Madrigal Pharmaceuticals Receives Positive CHMP Opinion for Resmetirom in Treating MASH Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) announced it granted equity awards on June 15, 2025, to 36 new non-executive employees under Madrigal’s 2023 Inducement Plan. The awards were …
Madrigal Pharmaceuticals Awards Equity Grants to New Employees Under 2023 Inducement Plan Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) will participate in the 46th Annual Goldman Sachs Health Care Conference on Wednesday, June 11, 2025, at 10:40 A.M. EDT.
Madrigal Pharmaceuticals to Present at 46th Annual Goldman Sachs Health Care Conference Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has announced two-year results from the open-label arm of its Phase 3 MAESTRO-NAFLD-1 trial, showcasing the potential of Rezdiffra for treating patients …
Madrigal Pharmaceuticals Reports Promising Two-Year Data for Rezdiffra in MASH Cirrhosis Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) is set to showcase critical new findings on resmetirom, its liver-targeted thyroid hormone receptor (THR)-β agonist, at the European Association for the …
Madrigal Pharmaceuticals to Present Breakthrough Resmetirom Data at EASL Congress 2025 Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has announced a key leadership transition as founder and Chief Medical Officer Dr. Rebecca Taub steps into the role of Senior Scientific …
Leadership Changes at Madrigal Pharmaceuticals Mark New Phase of Growth Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has announced the appointment of Jacqualyn (“Jackie”) Fouse, Ph.D., to its Board of Directors, bringing decades of leadership and expertise in the biotech …
Madrigal Pharmaceuticals Announces Changes to Board of Directors Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has announced its financial results for 2024, marking a pivotal year highlighted by the FDA approval and successful launch of Rezdiffra (resmetirom). Rezdiffra, …
Madrigal Pharmaceuticals Reports Strong 2024 Growth Fueled by Rezdiffra Launch Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has announced positive two-year results from the Phase 3 MAESTRO-NAFLD-1 trial, demonstrating the potential of Rezdiffra (resmetirom) to significantly reduce liver stiffness in …
Madrigal Pharmaceuticals Reports Promising Two-Year Results for MASH Therapy Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) has announced its participation in the 45th Annual TD Cowen Health Care Conference, scheduled to take place on Tuesday, March 4, 2025, …
Madrigal Pharmaceuticals to Present at 45th Annual TD Cowen Health Care Conference Read More